中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

49 records (took 0.028 seconds)

    아자티오프린을 유효성분으로 함유하는 뇌종양 또는 테모달 내성 교모세포종 예방 또는 치료용 약학적 조성물
    31.
    发明公开
    아자티오프린을 유효성분으로 함유하는 뇌종양 또는 테모달 내성 교모세포종 예방 또는 치료용 약학적 조성물 有权
    用于预防或治疗具有作为活性成分的含有阿拉伯糖的模拟物抗性的脑肿瘤或GLIOBLASTOMA的药物组合物

    公开(公告)号：KR1020140008645A

    公开(公告)日：2014-01-22

    申请号：KR1020120075365

    申请日：2012-07-11

    Applicant: 한국화학연구원 ,  사회복지법인 삼성생명공익재단

    Inventor： 조희영 ,  최길돈 ,  박우규 ,  정대영 ,  김현영 ,  이선경 ,  남도현 ,  설호준

    IPC: A61K31/52 ,  A61K31/519 ,  A61K31/4164 ,  A61P35/00

    CPC classification number: A61K31/52 ,  A61K31/495

    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancers or Temodal-resistant glioblastoma, containing azathioprine as an active ingredient. The azathioprine according to the present invention effectively suppresses the proliferation of glioblastoma, which is a kind of brain tumor, and exhibits an excellent therapeutic effect even on glioblastoma cancer cells having resistance to Temodal (temozolomide), which is an existing agent for treating glioblastoma. Therefore, the azathioprine according to the present invention can be useful as an active ingredient of a pharmaceutical composition for preventing or treating cancers such as brain tumors (especially, glioblastoma) and Temodal-resistant glioblastoma. [Reference numerals] (AA) Inhibition ratio (%)

    Abstract translation: 本发明涉及含有硫唑嘌呤作为有效成分的用于预防或治疗癌症或耐炎性胶质母细胞瘤的药物组合物。 根据本发明的硫唑嘌呤有效地抑制了作为一种脑肿瘤的胶质母细胞瘤的增殖，并且甚至对具有抗肿瘤成分（替莫唑胺）的成胶质细胞瘤癌细胞也是显示出优异的治疗效果，其是用于治疗胶质母细胞瘤的现有药剂。 因此，根据本发明的硫唑嘌呤可以用作用于预防或治疗诸如脑肿瘤（特别是成胶质细胞瘤）和耐甲状腺成胶质细胞瘤的癌症的药物组合物的活性成分。 （附图标记）（AA）抑制率（％）

    도파민 Ｄ４ 수용체 길항제로 유용한 피라졸부틸 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
    32.
    发明公开
    도파민 Ｄ４ 수용체 길항제로 유용한 피라졸부틸 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 有权
    吡咯啉化合物作为多巴胺D4受体拮抗剂，其制备方法和含有其的药物组合物

    公开(公告)号：KR1020120050841A

    公开(公告)日：2012-05-21

    申请号：KR1020100112296

    申请日：2010-11-11

    Applicant: 한국화학연구원

    Inventor： 박우규 ,  공재양 ,  조희영 ,  정대영 ,  최길돈 ,  고훈영 ,  이희윤 ,  정선호 ,  이해황 ,  이정국 ,  서용완

    IPC: C07D403/06 ,  A61K31/496 ,  A61P25/00

    Abstract: PURPOSE: A pyrazole butyl compound and a pharmaceutical composition containing the same are provided to ensure dopamine D4 receptor affinity and to prevent and treat central nervous system diseases. CONSTITUTION: A pyrazole butyl compound and pharmaceutically acceptable salt thereof are denoted by chemical formula 1. The salt includes inorganic acid salt, organic acid salt, amino acid salt, alkali metal salt, or ammonium salt. A method for preparing the pyrazole butyl compounds comprises: a step of performing reductive amination of pyrazole aldehyde compound of chemical formula 2 with heterocycle compounds of chemical formula 3 under the presence of reducing agent and base. A pharmaceutical composition for treating central nervous system diseases contains 1-(4-chlorophenyl)-4-(4-(1-phenyl-3-propyl-1H-pyrazole-5-yl)butyl)piperazine(compound No. 33) or 1-(4-(1-phenyl-3-propyl-1H-pyrazole-5-yl)butyl)-4-(3-(trifluoromethyl)phenyl)piperazine(compound No. 36).

    Abstract translation: 目的：提供吡唑丁基化合物和含有它们的药物组合物以确保多巴胺D4受体亲和力并预防和治疗中枢神经系统疾病。 构成：吡唑基丁基化合物及其药学上可接受的盐由化学式1表示。盐包括无机酸盐，有机酸盐，氨基酸盐，碱金属盐或铵盐。 制备吡唑丁基化合物的方法包括：在还原剂和碱的存在下，用化学式3的杂环化合物进行化学式2的吡唑醛化合物的还原胺化的步骤。 用于治疗中枢神经系统疾病的药物组合物含有1-（4-氯苯基）-4-（4-（1-苯基-3-丙基-1H-吡唑-5-基）丁基）哌嗪（化合物33）或 1-（4-（1-苯基-3-丙基-1H-吡唑-5-基）丁基）-4-（3-（三氟甲基）苯基）哌嗪（化合物36）。

    도파민 Ｄ3, Ｄ4 수용체 길항제인 신규 3-(메톡시메틸)피라졸 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
    33.
    发明公开
    도파민 Ｄ3, Ｄ4 수용체 길항제인 신규 3-(메톡시메틸)피라졸 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물 失效
    作为DOPAMINE D3和D4受体拮抗剂的3-（甲氧基甲基）吡唑衍生物，其制备方法和含有它们的药物组合物

    公开(公告)号：KR1020110024940A

    公开(公告)日：2011-03-09

    申请号：KR1020090083133

    申请日：2009-09-03

    Applicant: 한국화학연구원 ,  인하대학교 산학협력단

    Inventor： 고훈영 ,  김지희 ,  카말키숄포파트로랜지 ,  공재양 ,  박우규 ,  조희영 ,  정대영 ,  최길돈 ,  이희윤

    IPC: C07D403/08 ,  C07D403/06 ,  A61K31/415 ,  A61P25/18

    Abstract: PURPOSE: A pharmaceutical composition containing a novel 3-(methoxymethyl)pyrazole derivative is provided to ensure dopamine D3 and D4 receptor affinity and to suppress psychotic behavior(cage climbing) in a mouse. CONSTITUTION: A novel 3-(methoxymethyl)pyrazole derivative is denoted by chemical formula 1. The compound of chemical formula 1 is prepared by reductive amination of pyrazole aldehyde derivative of chemical formula 2 with piperazine derivative of chemical formula 3 under the presence of reductant and base. A pharmaceutical composition for treating central nervous system diseases contains the compound of chemical formula 1.

    Abstract translation: 目的：提供含有新的3-（甲氧基甲基）吡唑衍生物的药物组合物，以确保多巴胺D3和D4受体的亲和力，并抑制小鼠的精神病性行为（笼养）。 组成：化学式1表示新的3-（甲氧基甲基）吡唑衍生物。化学式1的化合物通过化学式2的吡唑醛衍生物与化学式3的哌嗪衍生物在还原剂的存在下还原胺化而制备， 基础。 用于治疗中枢神经系统疾病的药物组合物含有化学式1的化合物。

    2-메틸-2Ｈ-크로멘-2-카르복사미드 화합물
    34.
    发明公开
    2-메틸-2Ｈ-크로멘-2-카르복사미드 화합물 有权
    2-甲基-2H-色烯-2-羧酰胺化合物

    公开(公告)号：KR1020110012090A

    公开(公告)日：2011-02-09

    申请号：KR1020090069647

    申请日：2009-07-29

    Applicant: 한국화학연구원 ,  에스케이케미칼주식회사

    Inventor： 공영대 ,  조희영 ,  이태호 ,  최길돈 ,  전문국 ,  박우규 ,  공재양 ,  황순희 ,  정대영 ,  이봉용 ,  엄기안 ,  김재선 ,  류근호 ,  류제호 ,  김신애 ,  한혜영 ,  손현주 ,  이현정 ,  김용혁 ,  박성훈

    IPC: C07D311/24 ,  C07D311/16 ,  C07D311/12

    Abstract: PURPOSE: A 2-methyl-2H-chromen-2-carboxamide compound is provided to ensure selective suppression to 11beta-HSD1 enzyme and prevent and treat glucocorticoid regulatory disease. CONSTITUTION: A 2-methyl-2H-chromen-2-carboxamide compound is denoted by chemical formula 1. A pharmaceutical composition contains the 2-methyl-2H-chromen-2-carboxamide compound. The pharmaceutical composition is used for treating and preventing type 1 and 2 diabetes, injured glucose resistance, hyperlipidemia or hypertension. The 2-methyl-2H-chromen-2-carboxamide compound in which an amide is induced is obtained by condensing R1-substituted 2-methyl-2H-chromen-2-carboxy acid compound of chemical formula 2 with amine compound(NHR^2R^3).

    Abstract translation: 目的：提供2-甲基-2H-色烯-2-甲酰胺化合物，以确保对11beta-HSD1酶的选择性抑制，并预防和治疗糖皮质激素调节性疾病。 构成：2-甲基-2H-色烯-2-甲酰胺化合物由化学式1表示。药物组合物含有2-甲基-2H-色烯-2-甲酰胺化合物。 药物组合物用于治疗和预防1型和2型糖尿病，葡萄糖耐量受损，高脂血症或高血压。 通过将化学式2的R1取代的2-甲基-2H-色烯-2-羧酸化合物与胺化合物（NHR 2 R 2） ^ 3）。

    2-(2-아미도메틸)-2-메틸-2Ｈ-벤조피란 화합물
    35.
    发明公开
    2-(2-아미도메틸)-2-메틸-2Ｈ-벤조피란 화합물 有权
    2-（2-氨基甲基）-2-甲基-2H-苯并噻吩化合物

    公开(公告)号：KR1020110012089A

    公开(公告)日：2011-02-09

    申请号：KR1020090069646

    申请日：2009-07-29

    Applicant: 한국화학연구원 ,  에스케이케미칼주식회사

    Inventor： 공영대 ,  조희영 ,  이태호 ,  최길돈 ,  전문국 ,  박우규 ,  공재양 ,  황순희 ,  정대영 ,  이봉용 ,  엄기안 ,  김재선 ,  류근호 ,  류제호 ,  김신애 ,  한혜영 ,  손현주 ,  이현정 ,  김용혁 ,  박성훈

    IPC: C07D311/58 ,  C07D311/04 ,  C07D311/02

    Abstract: PURPOSE: A 2-(2-amido methyl)-2-methyl-2H-benzypyrane compound is provided to ensure selective suppression to 11 beta-HSD 1 enzyme and to prevent and treat clucocorticoid regulatory diseases. CONSTITUTION: A 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound is denoted by chemical formula 1. The 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound is 3-methoxy-N-methyl-N-[(2-methyl-8-nitro-2H-chromen-2-yl)methyl]benzamide or 3-chloro-N-[(2,6-dimethyl-2H-chromen-2-yl)methyl]-N-methylbenzamide. A pharmaceutical composition contains the 2-(2-amido methyl)-2-methyl-2H-benzopyrane compound and prevents and treats impaired glucose tolerance(IGT), type 1 and 2 diabetes, insulin resistance, dyslipidemia or hypertension.

    Abstract translation: 目的：提供2-（2-氨基甲基）-2-甲基-2H-苯并吡喃化合物，以确保对11β-HSD 1酶的选择性抑制，并预防和治疗类皮质激素调节性疾病。 构成：2-（2-氨基甲基）-2-甲基-2H-苯并吡喃化合物由化学式1表示。2-（2-酰氨基甲基）-2-甲基-2H-苯并吡喃化合物是3-甲氧基 - N-甲基-N - [（2-甲基-8-硝基-2H-色烯-2-基）甲基]苯甲酰胺或3-氯-N - [（2,6-二甲基-2H-色烯-2-基） 甲基] -N-甲基苯甲酰胺。 药物组合物含有2-（2-酰氨基甲基）-2-甲基-2H-苯并吡喃化合物，并预防和治疗葡萄糖耐量异常（IGT），1型和2型糖尿病，胰岛素抵抗，血脂异常或高血压。

    결명자 추출물 또는 이로부터 분리된 에모딘을 포함하는미백용 피부 외용 조성물
    37.
    发明公开
    결명자 추출물 또는 이로부터 분리된 에모딘을 포함하는미백용 피부 외용 조성물 失效
    用于外部应用于包含CASSIA TORA或EMODIN种子提取物的皮肤的组合物

    公开(公告)号：KR1020070095715A

    公开(公告)日：2007-10-01

    申请号：KR1020060026255

    申请日：2006-03-22

    Applicant: 한국화학연구원

    Inventor： 조희영 ,  공재양 ,  이성진 ,  정대영 ,  박우규 ,  김호정 ,  최길돈

    IPC: A61K8/97 ,  A61Q19/02

    Abstract: An external skin composition for skin whitening comprising the extract of Cassia tora or emodin isolated therefrom is provided to inhibit maturation and differentiation of melanin cells by inhibiting activity of c-Kit participating in signal transfer related to promotion of melanin synthesis caused by ultraviolet rays. An external skin composition for skin whitening comprises the extract of Cassia tora which is prepared by extracting Cassia tora with water, C1-C4 alcohol, mixed solvents thereof or chloroform, or emodin extracted from the Cassia tora extract which is obtained by extracting Cassia tora with methanol, fractioning the methanol extract with hexane and chloroform sequentially to obtain a chloroform fraction, and subjecting the chloroform fraction to the column chromatography using mixed solvents containing chloroform and methanol in a volume ratio of 20:1 to 5:1, and is a pharmaceutical composition for preventing and treating hemochromatosis or a cosmetic composition for skin whitening.

    Abstract translation: 提供皮肤美白的外用皮肤组合物，其包含从其中分离的决明子或大黄素的提取物，以通过抑制参与与由紫外线引起的促进黑色素合成相关的信号传递的c-Kit的活性来抑制黑色素细胞的成熟和分化。 用于皮肤美白的外用皮肤组合物包括通过用水，C1-C4醇，其混合溶剂或氯仿萃取决明子制备的桂皮提取物，或从通过将Cassia tora萃取得到的大黄素提取物中提取的大黄素， 甲醇，依次用己烷和氯仿分取甲醇提取物，得到氯仿馏分，并用氯仿和甲醇的体积比为20:1〜5:1的混合溶剂对氯仿馏分进行柱色谱分离，为药物 用于预防和治疗血色素沉着的组合物或用于皮肤美白的化妆品组合物。

Patent Agency Ranking